YAVNE, Israel--(BUSINESS WIRE)--
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in severe
burn and wound management, today announced that Company management will
participate at the Oppenheimer 25th Annual Healthcare
Conference taking place from December 10-11, 2014 in New York City. Gal
Cohen, President and Chief Executive Officer of MediWound, will be
presenting a corporate overview on Thursday, December 11th at
3:20 p.m. Eastern time.
Mr. Cohen's presentation will broadcast live and can be accessed by
visiting the investors section of the company's website at www.mediwound.com.
A replay of the webcast will be archived on the MediWound website for 90
days following the presentation.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on
developing, manufacturing and commercializing novel therapeutics based
on its patented proteolytic enzyme technology to address unmet needs in
the fields of severe burns, as well as chronic and other hard-to-heal
wounds. MediWound's first innovative biopharmaceutical product,
NexoBrid, received marketing authorization from the European Medicines
Agency for removal of dead or damaged tissue, known as eschar, in adults
with deep partial- and full-thickness thermal burns and has been
launched in Europe. NexoBrid represents a new paradigm in burn care
management, and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and, without harming viable tissues. For more
information, please visit www.mediwound.com.
MediWound Ltd.
Sharon Malka
Chief Financial & Operation
Officer
ir@mediwound.co.il
or
LHA
Anne
Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com
Source: MediWound Ltd.
News Provided by Acquire Media